Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics Inc (NQ: DYN )

29.50 -0.49 (-1.63%)
Streaming Delayed Price Updated: 2:57 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 467,243
Open 30.42
Bid (Size) 29.47 (7)
Ask (Size) 29.53 (7)
Prev. Close 29.99
Today's Range 29.35 - 30.85
52wk Range 10.03 - 47.45
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+125.88%
+125.88%
1 Month
-11.89%
-11.89%
3 Month
-37.29%
-37.29%
6 Month
-6.44%
-6.44%
1 Year
+180.69%
+180.69%

More News

Read More
Looking Into Dyne Therapeutics's Recent Short Interest
Via Benzinga
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Peering Into Dyne Therapeutics's Recent Short Interest
Via Benzinga
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
From Kirby McInerney LLP
Via Business Wire
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
Via Investor's Business Daily
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nasdaq Dips Over 2%; US Construction Spending Falls In July
Via Benzinga
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Dyne Therapeutics Announces Key Leadership Appointments
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
Via Talk Markets
Topics Stocks
Exposures US Equities
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.